Results 211 to 220 of about 796,056 (335)
Diffusion Tractography Biomarker for Epilepsy Severity in Children With Drug‐Resistant Epilepsy
ABSTRACT Objective To develop a novel deep‐learning model of clinical DWI tractography that can accurately predict the general assessment of epilepsy severity (GASE) in pediatric drug‐resistant epilepsy (DRE) and test if it can screen diverse neurocognitive impairments identified through neuropsychological assessments.
Jeong‐Won Jeong +7 more
wiley +1 more source
Continuous Wave-Diffuse Optical Tomography (CW-DOT) in Human Brain Mapping: A Review. [PDF]
Guan S +6 more
europepmc +1 more source
Whole-brain Optical Imaging: A Powerful Tool for Precise Brain Mapping at the Mesoscopic Level. [PDF]
Jiang T, Gong H, Yuan J.
europepmc +1 more source
Autism: Functional brain mapping of exceptional calendar capacity [PDF]
Nathalie Boddaert +5 more
openalex +1 more source
ABSTRACT Background Neurodegeneration with brain iron accumulation (NBIA) comprises a genetically and clinically heterogeneous group of rare neurological disorders characterized particularly by iron accumulation in the basal ganglia. To date, 15 genes have been associated with NBIA.
Seda Susgun +95 more
wiley +1 more source
A Different Kind of Brain Mapping: Curriculum Mapping in Neurology Residency Education. [PDF]
Nair S, Ahn HE, Sim MS, Fu KA.
europepmc +1 more source
ABSTRACT Background Apolipoprotein ε4 (APOE ε4) is a potent genetic risk factor for Alzheimer's disease (AD). However, its role in cerebral small vessel disease (CSVD) remains unclear. Given the clinical and pathological similarities between CSVD and AD, this study aimed to investigate the associations of APOE ε4 gene dosage with cognitive function and
Tingru Jin +6 more
wiley +1 more source
Whole-brain mapping in adult zebrafish and identification of the functional brain network underlying the novel tank test. [PDF]
Rajput N +6 more
europepmc +1 more source
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu +9 more
wiley +1 more source

